Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1

Reuters

Nov 10

Akari <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1

Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate $(ADC)$ candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p<0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582874803"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582874803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582874803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582874803","market":"us","top_or_hot":-1,"title":"Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p&lt;0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akari <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p&lt;0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL2x5xyp:1","article_id":"2582874803","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582874803","pubTimestamp":1762781759,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate  candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla + anti-PD1 , were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKTX":"Akari Therapeutics PLC","BK4007":"制药"},"translate_title":"Akari Therapeutics公布了新型剪接靶向ADC有效负载PH1的有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTX":0.9},"content_text":"Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1\n    \n\n        Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate $(ADC)$ candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla® + anti-PD1 (74% vs 42%, p<0.05), were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}